FOLH1 expression

Moreover, [ 68 Ga]-Ga-PSMA-DIM maintained relatively high uptake in LNCaP and 22Rv1 tumors even after 3 h (3.84 ± 0.50 %ID/mL and 3.59 ± 0.57 %ID/mL, respectively). In conclusion, [ 68 Ga]-Ga-PSMA-DIM could sensitively and specifically differentiate models with varying PSMA expression levels and show notable retention in vivo.

While EC1169 showed limited activity, CTC and imaging analyses showed significant heterogeneity in PSMA expression on CTCs in patients with predominantly PSMA-positive lesions on SPECT. Our study highlights the importance of assessing both PSMA-based CTC and imaging assays in future validation trials.

P1, N=10, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

Available therapeutic options include radioligand therapy (e.g. lutetium-177-PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. Finally, the review provides an overview of promising emerging therapies poised to expand the treatment landscape for mCRPC. These include bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates, which are currently under investigation in clinical trials and may soon offer new avenues for treatment beyond traditional mechanisms.

Several adverse pathological features of primary CRC were associated with a lower PSMA expression in hepatic metastasis. PSMA expression in hepatic metastasis correlated with that of primary CRC only in concurrent and untreated subgroup. Primary HCC and hepatic CRC metastasis show comparable levels of PSMA expression.

P=N/A, N=102, Recruiting, Martini-Klinik am UKE GmbH | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jan 2026

High PSMA expression in differentiated thyroid cancer was associated with shorter progression-free survival and may be considered a marker of aggressiveness. Such tumors could be candidates for targeted PSMA-radioligand therapy (e.g., 177 lutetium), particularly in radioiodine-negative/refractory cases, which are difficult to treat.

Question While prostate-specific membrane antigen (PSMA)-PET has become essential in the management of prostate cancer, indeterminate bone lesions and lymph nodes remain challenging to address. Findings A multidisciplinary algorithm for interpreting indeterminate bone lesions and lymph nodes on PSMA-PET, incorporating clinicopathological information and multimodality imaging, reduced the frequency of equivocal interpretations. Clinical relevance An algorithm for interpreting indeterminate bone lesions and lymph nodes on PSMA-PET, incorporating clinicopathological information and multimodality imaging in a multidisciplinary tumor board setting, decreases the frequency of equivocal interpretations and can potentially help management decisions.

This rare case demonstrates intense 18F-PSMA-1007 uptake in a colonic diverticulum, likely attributable to PSMA expression by neovascular endothelium or inflammatory cells. Clinicians should consider colonic diverticulum in the differential diagnosis of PSMA-avid colonic lesions to prevent misdiagnosis.

We describe 68Ga-PSMA-11 PET/CT and delayed abdominal 68Ga-PSMA-11 PET/MRI findings in a case of mass-forming type of perihilar cholangiocarcinoma. The tumor showed intense PSMA uptake with SUVmax of 10.8 on 68Ga-PSMA-11 PET/CT and SUVmax of 7.8 on delayed 68Ga-PSMA-11 PET/MRI.

The expanding global use of PSMA PET has increasingly revealed PSMA ligand uptake in a variety of non-prostatic benign and malignant conditions, creating false positive results. Our case highlights that pituitary macroadenoma may have strong PSMA expression and should be recognized as a potential imaging pitfall.

[68Ga]Ga-OncoACP3-DOTA changed therapeutic management in three of six patients with biochemical recurrence, and in two of 12 patients with known metastases. Although the retrospective comparison is potentially biased, the intense and reliable tumor uptake and the low off-target activity of OncoACP3-DOTA provide a strong rationale for future exploration in trials on PET imaging and radioligand therapy with β- and α-particle emitters.